



Universiteit
Leiden
The Netherlands

Alternate Splicing of the p53 Inhibitor HDMX Offers a Superior Prognostic Biomarker than p53 Mutation in Human Cancer

Lenos, K.; Grawenda, A.M.; Lodder, K.; Kuijjer, M.L.; Teunisse, A.F.A.S.; Repapi, E.; ... ; Jochemsen, A.G.

Citation

Lenos, K., Grawenda, A. M., Lodder, K., Kuijjer, M. L., Teunisse, A. F. A. S., Repapi, E., ... Jochemsen, A. G. (2012). Alternate Splicing of the p53 Inhibitor HDMX Offers a Superior Prognostic Biomarker than p53 Mutation in Human Cancer. *Cancer Research*, 72(16), 4074-4084.
doi:10.1158/0008-5472.CAN-12-0215

Version: Not Applicable (or Unknown)
License: [Leiden University Non-exclusive license](#)
Downloaded from: <https://hdl.handle.net/1887/97477>

Note: To cite this publication please use the final published version (if applicable).

Alternate Splicing of the p53 Inhibitor HDMX Offers a Superior Prognostic Biomarker than p53 Mutation in Human Cancer

Kristiaan Lenos¹, Anna M. Grawenda³, Kirsten Lodder¹, Marieke L. Kuijjer², Amina F.A.S. Teunisse¹, Emmanouela Repapi³, Lukasz F. Grochola³, Frank Bartel⁴, Pancras C.W. Hogendoorn², Peter Wuerl⁵, Helge Taubert⁶, Anne-Marie Cleton-Jansen², Gareth L. Bond³, and Aart G. Jochemsen¹

Abstract

Conventional high-grade osteosarcoma is the most common primary bone malignancy. Although altered expression of the p53 inhibitor HDMX (Mdmx/Mdm4) is associated with cancer risk, progression, and outcome in other tumor types, little is known about its role in osteosarcoma. High expression of the Hdmx splice variant *HDMX-S* relative to the full-length transcript (the *HDMX-S/HDMX-FL* ratio) correlates with reduced HDMX protein expression, faster progression, and poorer survival in several cancers. Here, we show that the *HDMX-S/HDMX-FL* ratio positively correlates with less HDMX protein expression, faster metastatic progression, and a trend to worse overall survival in osteosarcomas. We found that the *HDMX-S/HDMX-FL* ratio associated with common somatic genetic lesions connected with p53 inhibition, such as p53 mutation and HDM2 overexpression in osteosarcoma cell lines. Interestingly, this finding was not limited to osteosarcomas as we observed similar associations in breast cancer and a variety of other cancer cell lines, as well as in tumors from patients with soft tissue sarcoma. The *HDMX-S/HDMX-FL* ratio better defined patients with sarcoma with worse survival rates than p53 mutational status. We propose a novel role for alternative splicing of *HDMX*, whereby it serves as a mechanism by which HDMX protein levels are reduced in cancer cells that have already inhibited p53 activity. Alternative splicing of *HDMX* could, therefore, serve as a more effective biomarker for p53 pathway attenuation in cancers than p53 gene mutation. *Cancer Res*; 72(16); 4074–84. ©2012 AACR.

Introduction

Osteosarcoma is the most common primary bone malignancy in children and adolescents, occurring mostly in patients between 10 and 25 years of age and found in the rapid growth areas of the long bones (1). The vast majority of osteosarcomas arise without a clear hereditary component, with the exception of a small subset including individuals with the Li-Fraumeni

and progeria syndromes. Overall long-term (5-year) survival for patients with nonmetastatic osteosarcomas has increased from 10% to 65% over the past 20 years, due to improved surgical techniques and multidrug chemotherapy, but further improvement is needed (2). Indeed, 25% to 50% of patients will relapse or metastasize and 5-year survival rate for metastatic osteosarcomas is only 10% to 20% (3, 4). It is clear that additional therapies are required to increase the survival of patients with osteosarcoma.

Authors' Affiliations: Departments of ¹Molecular Cell Biology and ²Pathology, Leiden University Medical Center, Leiden, The Netherlands; ³Ludwig Institute for Cancer Research, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom; ⁴Institute of Pathology, Faculty of Medicine, University of Halle-Wittenberg; ⁵Department of General and Visceral Surgery, Diakonie-Hospital Halle; and ⁶Division Molecular Urology, University Clinic of Urology and Nikolaus-Fiebiger-Center for Molecular Medicine, FAU Erlangen-Nürnberg, Erlangen, Germany

In approximately 50% of all human cancers mutations are found in the p53 gene, which encodes the tumor suppressor protein p53 (5–7). Indeed, it has been clearly shown that in many of the remaining 50% of cancers, the activity of the wild-type p53 protein is greatly attenuated (8). In high-grade osteosarcoma, mutations in the p53 gene are found in only 20% of the tumors (9–11). However, the genomic region that encodes for a key negative regulator of p53, HDM2 (12, 13), was found to be amplified in 10% to 35% of osteosarcomas and these amplifications were shown to be mutually exclusive to p53 mutations (9–11, 14).

Note: Supplementary data for this article are available at Cancer Research Online (<http://cancerres.aacrjournals.org/>).

The Department of Pathology, Leiden University Medical Center, is partner of the EuroBoNeT consortium, a European commission granted Network of Excellence for studying the pathology and genetics of bone tumors.

K. Lenos and A.M. Grawenda contributed equally to this work.

Corresponding Authors: Aart G. Jochemsen, Department of Molecular Cell Biology, Leiden University Medical Center, P.O. Box 9600, S1-P, 2300 RC Leiden, The Netherlands. E-mail: A.G.Jochemsen@lumc.nl; and Gareth L. Bond, The Nuffield Department of Medicine, The Ludwig Institute for Cancer Research, The University of Oxford, Oxford OX3 7DQ, United Kingdom. Phone: 44-0-1865-617497; Fax: 44-0-1865-617515; E-mail: Gareth.Bond@ndm.ox.ac.uk

In many of the studies that were aimed at determining the importance of the inactivation of the p53 pathway during the progression of osteosarcoma, only p53 mutational status was studied and the level of HDM2 protein expression was not included, resulting in the possible underestimation of the influence of p53 inactivation on prognosis. Moreover, the somatic mutation or alteration of other crucial effectors of p53 activity has also been understudied in osteosarcoma. For example, the oncogene *HDMX* is a close homolog of *HDM2* and

doi: 10.1158/0008-5472.CAN-12-0215

©2012 American Association for Cancer Research.

encodes a protein product, which also clearly inhibits p53 activity (15, 16). In several tumor types, overexpression and amplification of *HDMX* has been shown both in tumors (17, 18) and tumor-derived cell lines and is primarily found in tumors that have retained wild-type p53 (19). Indeed, 2 tumor types that have a very low frequency of p53 gene mutation (retinoblastomas and Ewing sarcomas) have showed elevated HDMX expression (20, 21).

In sarcomas, amplification of the *HDMX* gene has been found in both soft tissue sarcomas (STS, 16%–17%) and osteosarcomas (35%; refs. 14, 22). Bartel and colleagues showed a significant association between *HDMX* amplification and poor prognosis after initial STS diagnosis (22). In addition, they showed that the mRNA expression of an alternative splice variant of Hdmx, *HDMX-S*, is upregulated in 14% of STS and that an increase in the ratio of the transcript levels of the splice variant over full-length (the *HDMX-S/HDMX-FL* ratio) correlates with a higher tumor grade at diagnosis and decreased overall survival (22). The *HDMX-S/HDMX-FL* ratio was also found to be increased in high-grade glioblastomas (17) and papillary thyroid carcinomas (23). The *HDMX-S* transcript results from the exclusion of exon 6 (24), resulting in a truncated protein essentially consisting of the p53-binding domain, which in overexpression studies, was found to be stronger inhibitor of p53 shown to bind to and inhibit p53 more efficiently (24). Although studies such as these suggest an oncogenic role for the HDMX-S protein, no conclusive evidence has been published to date to suggest that the protein is produced and active in cells (25). Indeed, our previous work suggests that an increase in the *HDMX-S/HDMX-FL* ratio associates primarily with reduced levels of full-length HDMX protein (25).

Here, we report further on the alterations in the *HDMX-S/HDMX-FL* ratio in relation with p53 status and cancer progression. The results indicate that changes in the *HDMX-S/HDMX-FL* ratio could serve as a more effective biomarker for p53 pathway attenuation in cancers than p53 gene mutation.

Materials and Methods

Patient material

Osteosarcoma cohort. Clinicopathologic data of 51 patients with osteosarcoma are shown in Supplementary Table S1. Part of the samples was previously described (26). Biopsies were taken before preoperative chemotherapeutics were administered. The differences in response to chemotherapy were classified as good or poor, using the Huvos criteria (27). All tissue samples were handled according to the National Ethical Guidelines (Code for Proper Secondary Use of Human Tissue in The Netherlands, Dutch Federation of Medical Scientific Societies).

STS cohort. The clinicopathologic data of the 157 patients with STS included in this study are shown in Supplementary Table S2. A subset was previously described (22). Tumor samples were taken before adjuvant radio- and/or chemotherapeutics were administered. The study adhered to national regulations on ethical issues and was approved by the local ethical committee. All patients gave written and informed

consent (Department of Surgery I, University of Leipzig, Leipzig, Germany).

Cell culture and reagents

Cell lines were maintained in RPMI supplemented with 10% FBS and antibiotics. Most of the osteosarcoma cell lines have been described recently, including their genotyping and detailed methods on p53 sequencing (28). Osteosarcoma cell lines L2531, L2635, L2792, L2826, L2857, and L2962 were recently established at the Department of Molecular Cell Biology, LUMC (Leiden, The Netherlands) in the laboratory of Dr. Szuhai. Status of p53 gene was determined as described by da Costa and colleagues (29). Tumor, normal, and cell line DNA was typed to confirm cell line identity with use of the Cell ID system of Promega. Normal osteoblasts were obtained as described previously (30). Breast cancer cell lines were a gift from Mieke Schutte (Erasmus MC, Rotterdam, The Netherlands). The origin of all breast cancer cell lines and verification of their individual identity has been described previously, including a full description of the p53 gene sequencing (31, 32). RNA and protein was extracted from the cells within 5 passages after receipt. All cell lines are routinely tested for mycoplasma infection. To determine the p53 response cells were treated with 10 μ mol/L Nutlin-3 (Cayman Chemical) for the indicated times. The RNA from the NCI60 panel of cell lines was a generous contribution from the NCI-Division of Cancer Treatment and Diagnosis Repository Molecular Characterization Program.

RNA isolation, reverse transcription, semiquantitative PCR, and quantitative reverse transcription PCR

Osteosarcomas and breast cancer cell lines. RNA was isolated using the SV Total RNA Isolation System (Promega) according to the manufacturer's protocol, followed by cDNA synthesis following standard protocols. Semiquantitative PCR was carried out according to standard protocols; for detection of both *HDMX-FL* and *HDMX-S*, the HDMX ex3 forward 5'-TGATGTCAGCAGGTGCG-3' and the HDMX ex8 reverse 5'-CATTACTTCTAGGTGTAT-3' primers were used. For detection of glyceraldehyde-3-phosphate dehydrogenase (*GAPDH*), the *GAPDH* forward 5'-AATCCCATCACCATCTTCC-3' and the *GAPDH* reverse 5'-ATGAGTCCTCCACGATACC-3' primers were used.

Band intensities were quantified using Odyssey 2.1 analysis software (LI-COR Biosciences).

NCI60 cell lines. The cDNAs for the NCI60 cell lines panel were derived from RNAs obtained from the National Cancer Institute (NCI)/NIH Developmental Therapeutics Program (DTP), a recognized cell repository. The NCI60 panel of human tumor cell lines are some of the most extensively characterized cell lines. In regards to cell line identity, the cell lines have been characterized using many approaches, such as single-nucleotide polymorphism arrays, oligonucleotide base HLA typing, spectral karyotyping, screening for known cancer mutations, and variations in short tandem repeats. Much of these data can be found on the DTP website. The mRNA levels of *HDMX-S* and *HDMX-FL* were determined as described earlier. Measurements of *HDM2* transcript levels were carried

out by quantitative reverse transcription PCR (qRT-PCR) using commercially available RoboGeneMDM2 cDNA quantification module, with ABI PRISM 7000 Sequence Detection System. *HDM2* measurements were normalized to *GAPDH* transcript levels.

Soft tissue sarcomas. *HDMX-FL* and *HDMX-S* transcript levels were measured by quantitative real-time reverse transcriptase PCR as described (22). Briefly, the reactions were carried out on a Rotor-Gene 3000 (Corbett Research), with a common forward primer for both *FL-HDMX* and *HDMX-S*; X quant forward 5'-CAGCAGGTGCGCAAGGTGAA-3' and reverse primers specifically designed for amplification of either *FL-HDMX*, FL-AS 6 5'-CTGTGCGAGAGCGAGAGTCTG-3' or *HDMX-S*, XS AS 5'-GCACTTTGCTGTAGTAGCAGTG-3'. Each reaction included one tenth of the cDNA reaction, 10 μ L of 2 \times Quantitect SYBR Green Master Mix (Qiagen) and 20 pmol of the respective primers in a total volume of 20 μ L. The PCR consisted of 50 cycles with 30 seconds of denaturation at 95°C, 30 seconds of primer annealing at 58°C, and synthesis at 72°C for 30 seconds. The *HDMX-FL* and *HDMX-S* levels were normalized against *GAPDH* expression levels.

The p53 mutational status was assessed by sequencing exons 4 through 10.

Details of p53 sequencing are provided in Supplementary Information.

Protein extraction, Western blotting, and antibodies

Protein extraction and immunoblotting were carried out as described previously (33). Anti-HDMX and anti-USP7 (A300-

287A, A300-033A) were from Bethyl Laboratories. Anti-p53 PAb1801 and DO-1, anti-HDM2 antibodies 4B2 (34) and SMP14 were from Santa Cruz Biotechnology. Secondary antibodies goat-anti-mouse-HRP and goat-anti-rabbit-HRP were obtained from Jackson Laboratories.

Statistical analysis

The GraphPad Instat version 3.06 software was used to compare means. The Kaplan–Meier and Cox multivariate regression survival analyses and the analyses of contingency tables were conducted using the SPSS 19.0 software. Statistical significance was regarded as $P < 0.05$.

Results

The *HDMX-S/HDMX-FL* ratio in osteosarcoma

To further explore the importance of the p53 pathway during the progression of osteosarcoma, we initially analyzed the *HDMX-S/HDMX-FL* ratio and its association with HDMX protein levels in 22 osteosarcoma cell lines. The levels of *HDMX-S* and *HDMX-FL* mRNA were determined in logarithmically growing cells for all 22 osteosarcoma cell lines and 1 osteoblast. Semiquantitative PCR was carried out using primers designed to amplify exons 3 to 8 (Fig. 1A). The intensities of the bands for *HDMX-S* and *HDMX-FL* were quantified and normalized to *GAPDH* expression levels (Fig. 1B) and results are summarized in Supplementary Table S3. The protein levels of HDMX were also determined from logarithmically growing cells (Fig. 1C). The intensities of the band corresponding to HDMX were quantified and normalized to USP7 levels (Supplementary




Figure 1. Analysis of *HDMX-S* in 22 osteosarcoma cell lines. A, schematic drawing of Hdmx protein structure (top) containing the p53-binding domain (p53-BD), acidic domain (AD), zinc-finger (Zn), and RING domain. Structure of *HDMX-FL* and *HDMX-S* mRNA is depicted below. Arrows indicate start and stop codons. Exon 6 is spliced out in *HDMX-S*, resulting in 26 novel amino acids and a premature stop codon. B, a total of 22 osteosarcoma cell lines and 1 osteoblast sample were examined for *HDMX-FL* and *HDMX-S* mRNA expression using primers for Hdmx exon 3 (Fw) to exon 8 (Rev). *GAPDH* mRNA expression was examined as an internal control. C, protein levels were analyzed with immunoblotting using the indicated antibodies. USP7 expression was analyzed as a loading control.

Figure 2. High *HDMX-S/HDMX-FL* ratios in 22 osteosarcoma cell lines associate with lower HDMX protein levels. A, column graph depicting the number of cells with a given *HDMX-S/HDMX-FL* ratio, whereby a normal distribution is observed. B, graph depicting the negative correlation of the *HDMX-S/HDMX-FL* ratio on the y-axis with HDMX protein levels on the x-axis. C, column graph depicting the average HDMX protein levels for the groups of cell lines with varying ratios of *HDMX-S/HDMX-FL*, whereby cells with higher ratios contain less HDMX protein. The error bars depict standard errors.




Table S3). The *HDMX-S/HDMX-FL* ratios varied from 0.39 to 3.18 with a median of 1.5, an SD of 0.7, and a normal distribution (Fig. 2A). Interestingly, the *HDMX-S/HDMX-FL* ratio significantly negatively correlated with the measured HDMX protein levels ($P = 0.004$, Fig. 2B). Specifically, those 5 cells with the highest *HDMX-S/HDMX-FL* ratios had 9.5-fold less HDMX protein than those 5 cells with the lowest ratios (t test, $P = 0.0238$, Fig. 2C).

To explore the potential association of the *HDMX-S/HDMX-FL* ratio with osteosarcoma progression and survival, we studied 51 patients with high-grade osteosarcoma from Germany, Holland, and Italy (Supplementary Table S1). The patients consisted of 32 males and 19 females with an average age of diagnosis of 17.5 years, ranging from 3 to 58 years. The levels of *HDMX-S* and *HDMX-FL* were determined in biopsies that were taken before preoperative chemotherapy. The level of each transcript was determined in 49 of the samples (Fig. 3A, Supplementary Table S4) and the intensities of the bands for *HDMX-S* and *HDMX-FL* were quantified and normalized to *GAPDH* expression levels. The *HDMX-S/HDMX-FL* ratios varied from 0.38 to 4.86 with a median of 1.3 and an SD of 1. Interestingly, the distribution of the *HDMX-S/HDMX-FL* ratios was not normal ($P = 0.0011$). In fact, 11 tumors showed very high ratios, as defined by one SD above the median (Fig. 3B).

To determine whether the *HDMX-S/HDMX-FL* ratios associated with progression of the high-grade osteosarcomas, we explored whether patients whose tumors had the highest *HDMX-S/HDMX-FL* ratios had a shorter time to metastasis than patients with the lowest ratios. The metastasis information was available for all patients with osteosarcoma. Of the 49

patients where the *HDMX-S/HDMX-FL* ratios were successfully determined, 38 patients had not yet presented metastasis upon inclusion in the study. Interestingly, when the patients were divided up into 3 equal groups based on the measured *HDMX-S/HDMX-FL* ratios in the tumors (12 low, 13 intermediate, and 13 high), those patients whose tumor had the highest ratios had the shortest time to metastasis and those with lowest ratios, the longest time (Fig. 3C, $P = 0.005$, log-rank test). Specifically, the 13 patients whose tumors had the highest *HDMX-S/HDMX-FL* ratios (average ratio of 2.55, ranging from 1.8–4.07) associated with a significantly shorter time of metastasis-free survival than the 12 whose tumors had the lowest ratios (average ratio of 0.8, ranging from 0.44–1.0). In 2.5 years, 62% of those with the highest *HDMX-S/HDMX-FL* ratios had presented with a metastasis, compared with only 8% of those with the lowest ratios. Similar trends were seen in overall survival, whereby the 13 patients with highest *HDMX-S/HDMX-FL* ratio associated with shorter overall survival than the 12 with the lowest ratios ($P = 0.072$, Fig. 3D).

These results show that the *HDMX-S/HDMX-FL* ratio positively correlates with less HDMX protein expression, faster metastatic progression, and worse overall survival of osteosarcoma. We propose that a reason a cancer cell would not retain the oncogenic activity of full-length HDMX could be because it has already inhibited p53 signaling by mutations of other key regulatory genes in the pathway and, therefore, is no longer under selective pressure to sustain high levels of HDMX. If true, cancer cells with higher *HDMX-S/HDMX-FL* ratios should associate with higher frequencies of other p53 pathway mutations. To test this possibility, we determined the status of




Figure 3. Analysis of *HDMX-S* mRNA expression in osteosarcoma biopsies and its association with worse clinical outcome. **A**, the expression patterns of *HDMX-FL* and *HDMX-S* mRNA in 51 osteosarcoma biopsies, normal osteoblasts, and breast cancer cell line MCF7, analyzed by semiquantitative PCR with *HDMX* primers in exon 3 (FW) and exon 8 (Rev). **B**, column graph depicting the number of biopsies with a given *HDMX-S/HDMX-FL* ratio. **C** and **D**, Kaplan–Meier plots displaying the metastasis free survival (**C**) or overall survival (**D**) for patients whose biopsies contain high ($n = 13$), intermediate ($n = 13$), or low *HDMX-S/HDMX-FL* ratios ($n = 12$). The P values are derived from a log-rank test comparing patients with high ratios to those with low ratios, as is depicted by the asterisk.

2 well-characterized somatic alterations that result in p53 inhibition, p53 gene mutation, and overexpression of HDM2, in all 22 osteosarcoma cell lines. The protein levels of HDM2 were determined in logarithmically growing cells and normalized to USP7 levels (Fig. 1C; Supplementary Table S3). The p53 status of all 22 osteosarcoma cell lines was determined using a combination of direct sequencing, p53 mRNA measurements, and measurements of the response of each cell line to Nutlin-3, a small-molecule inhibitor of the p53-HDM2 interaction that activates p53 signaling (35). A cell line was only deemed to have functional wild-type p53 if no mutations were found in exons 3 to 11, it expressed detectable levels of p53 mRNA and protein, and responded to Nutlin-3 treatment, as measured by the determination of p53 and HDM2 protein levels (Supplementary Fig. S1A), reduced survival (Supplementary Fig. S1B), and inhibition of cell-cycle progression (Supplementary Fig. S1C). Of the 22 cell lines, only 6 lines were deemed to be wild-type for p53 (Supplementary Table S3). Interestingly, and in support of the hypothesis above, those 6 cell lines contained significantly lower *HDMX-S/HDMX-FL* ratios than the remaining 16 cell lines ($P = 0.0325$, Mann–Whitney test, Table 1). Similar trends

were observed when those cells retaining wild-type p53 and low levels of HDM2 were compared with those with wild-type p53 and higher levels of HDM2 ($P = 0.1$, Mann–Whitney test, Table 1), thereby lending further support to the hypothesis that higher *HDMX-S/HDMX-FL* ratios, and therefore lower HDMX protein levels, can arise in cancer cells that have already inhibited p53 signaling through alterations of other key p53 pathway genes.

The *HDMX-S/HDMX-FL* ratio in breast cancer and NCI60 cells

To test this hypothesis further, we explored the associations of the *HDMX-S/HDMX-FL* ratio in a panel of 37 cell lines derived from breast cancer, a tumor type that is clearly surveyed by the p53 pathway, and in which p53 mutational status of the tumor has clear prognostic value (36). We first determined the levels of *HDMX-S* and *HDMX-FL* (Fig. 4A). The HDMX, HDM2, and p53 protein levels and p53 mutational status in all 37 cells have been published before (32, 33). The results are summarized in Supplementary Table S5. The *HDMX-S/HDMX-FL* ratios varied from 0.12 to 4.35, with a median of 1.1 and an SD of 1.15. The

Table 1. The associations of the HDMXS/HDMX-FL ratios with p53 pathway mutations in 3 cell panels

			Ratio S/FL	
Osteosarcoma	p53 (n = 22)	wt (n = 6)	1.17	
		Mut (n = 16)	1.84	
			P	0.0325 ^a
	wt p53 (n = 6)	Low HDM2 (n = 3)	0.83	
High HDM2 (n = 3)		1.51		
		P	0.1 ^a	
Breast cancer	p53 (n = 37)	wt (n = 8)	0.69	
		Mut (n = 29)	1.76	
			P	0.0028 ^a
	wt p53 (n = 8)	Low HDM2 (n = 4)	0.34	
High HDM2 (n = 4)		1.03		
		P	0.343 ^a	
NCI60	p53 (n = 50)	wt (n = 14)	1.47	
		Mut (n = 36)	2.71	
			P	0.0227 ^a
	wt p53 (n = 14)	Low HDM2 (n = 7)	0.57	
High HDM2 (n = 7)		2.38		
		P	0.0728 ^a	
			0.0364 ^b	
All cell lines	p53 (n = 106)	wt (n = 27)	1.22	
		Mut (n = 79)	2.24	
			P	0.0001 ^a
	wt p53 (n = 27)	Low HDM2 (n = 13)	0.56	
High HDM2 (n = 14)		1.93		
		P	0.0116 ^a	

^aMann-Whitney test, 2-tail.^bMann-Whitney test, 1-tail.

distribution of the *HDMX-S/HDMX-FL* ratios is not normal ($P = 0.0241$). Of 37 cell lines 9 showed very high ratios, as defined by one SD above the median (Fig. 4B). Interestingly, the *HDMX-S/HDMX-FL* ratio significantly negatively correlated with measured HDMX protein levels ($P = 2.28 \times 10^{-8}$, Fig. 4C). Furthermore, when the cells were ranked by the measured *HDMX-S/HDMX-FL* ratios and subsequently divided into almost equal groups of 9, the groups with increasing ratios had significantly decreasing HDMX protein levels (Kruskal-Wallis test, $P = 0.0001$, Fig. 4D). Specifically, the 9 cell lines with the highest *HDMX-S/HDMX-FL* ratios had 9.87-fold less HDMX protein than the 9 cell lines with the lowest ratios (Mann-Whitney test, $P = 0.0002$).

The 8 breast cancer cell lines with wild-type p53 contained significantly lower *HDMX-S/HDMX-FL* ratios than the remaining 29 cell lines ($P = 0.0028$, Mann-Whitney test, Table 1). Similar differences were seen when we compared cells retaining wild-type p53 and low levels of HDM2 to those with wild-type p53 and high levels of HDM2 ($P = 0.343$, Mann-Whitney test, Table 1). To test this hypothesis further in another cell line

panel, we determined the *HDMX-S/HDMX-FL* ratios and measured *HDM2* mRNA levels in the National Cancer Institute 60 (NCI60) panel, which consists of 59 human cancer cell lines, representing 9 cancer types (Supplementary Table S6; ref. 37). Three cell lines overlap with the above-analyzed breast cancer cell panel. Of the 59 cell lines, 14 are known to have wild-type p53, 36 have either mutated or deleted p53, whereas for the remaining cell lines p53 status is inconclusive (38, 39). We determined the levels of *HDMX-FL* and *HDMX-S* mRNA (Supplementary Fig. S2A) and the levels of *HDM2* mRNA normalized to *GAPDH* using qRT-PCR (Supplementary Table S6). The *HDMX-S/HDMX-FL* ratios varied from 0 to 18.65, with a median of 1.25 and an SD of 3.3. The distribution of the *HDMX-S/HDMX-FL* ratios, similarly to the patients with breast cancer cell panel and osteosarcoma, was not normal (Supplementary Fig. S2B). Interestingly, we found that the 14 cell lines with wild-type p53 had significantly lower *HDMX-S/HDMX-FL* ratios than the remaining 36 cell lines lacking functional p53 ($P = 0.0227$, Mann-Whitney test, Table 1). Furthermore, a similar significant trend was observed when we compared *HDMX-S/HDMX-*




Figure 4. Analysis of the *HDMX-S/HDMX-FL* ratio and its association with HDMX protein levels in breast cancer cell lines. A, cell lines were examined for *HDMX-FL* and *HDMX-S* mRNA expression using primers for *Hdmx* exon 3 (FW) to exon 8 (Rev). B, column graph depicting the number of cells with a given *HDMX-S/HDMX-FL* ratio. C, graph depicting the negative correlation of the *HDMX-S/HDMX-FL* ratio on the y-axis with HDMX protein levels on the x-axis. D, column graph depicting the average HDMX protein levels for the groups of cell lines with varying ratios of *HDMX-S/HDMX-FL*, whereby cell lines with higher ratios contain less HDMX protein. The error bars depict standard errors.

FL ratios in the wild-type p53 cell lines with either high or low levels of *HDM2* mRNA. Specifically, the 7 cell lines with the lowest *HDM2* mRNA levels had significantly lower *HDMX-S/HDMX-FL* ratios than the 7 cell lines with the highest levels of *HDM2* ($P = 0.0364$, Mann-Whitney test, 1-tailed, Table 1).

Together, these observations made in 3 cell panels comprising a total of 115 different cell lines, lend support to a model that higher *HDMX-S/HDMX-FL* ratios, and therefore lower HDMX protein levels, arises in cancer cells that have attenuated p53 signaling through alterations of key p53 pathway genes. Indeed, we observed that the 27 cell lines with wild-type p53 in the 3 panels had significantly lower *HDMX-S/HDMX-FL* ratios than the 79 cell lines lacking functional p53 ($P = 0.0001$, Mann-Whitney test, Table 1). Furthermore, in the 27 wild-type p53 cell lines, the 13 lines with the lowest *HDM2* mRNA levels had significantly lower *HDMX-S/HDMX-FL* ratios than the 14 with the highest levels of *HDM2* ($P = 0.0116$, Mann-Whitney test, Table 1). When the 106 cell lines with p53 mutational status were separated into almost equal numbers after ranking based on the *HDMX-S/HDMX-FL* ratios, we observed that of the

35 lines with the lowest ratios, 12 (34%) had wild-type p53 and lower HDM2 levels. In contrast, in the 36 cell lines with the highest ratios, only 1 cell line (3%) had wild-type p53 and lower HDM2 levels ($P = 0.0006$, Fisher exact test, Fig. 5), than 4 of the 35 cell lines with intermediate ratios (11%, $P = 0.001$, Fisher exact test).

The *HDMX-S/HDMX-FL* ratio and p53 mutation as prognostic markers

Thus far in cells, we have observed that the cancer lines with higher *HDMX-S/HDMX-FL* ratios have significantly higher frequencies of 2 common p53 pathway mutations, namely p53 gene mutation and HDM2 overexpression (Table 1, Fig. 5). Inhibition of p53 signaling through p53 mutation has clearly been shown to have prognostic value in multiple cancers (36). If the proposed model is true, the *HDMX-S/HDMX-FL* ratio could potentially serve as a more effective prognostic biomarker than p53 gene mutation, because alterations of other key p53 pathway genes that result in p53 pathway attenuation could be captured simultaneously. To begin to explore this possibility,




Figure 5. Cancer lines with higher *HDMX-S/HDMX-FL* ratios have significantly higher frequencies of 2 common p53 pathway mutations, namely p53 gene mutation and HDM2 overexpression. Column graph depicting the percentage of cell lines with wild-type p53 and lower HDM2 in the 106 cell lines that are divided into 3 groups based on low, intermediate, and high expression of the *HDMX-S/HDMX-FL* ratio.

we compared the prognostic value of either p53 tumor mutation or the *HDMX-S/HDMX-FL* in another tumor type that is clearly surveyed by p53 signaling, namely STS, where an increase of the *HDMX-S/HDMX-FL* ratio has been shown to associate with altered survival (22).

We studied a cohort of 157 patients with STS from Germany (Supplementary Table S2). We were able to receive ample tumor material from 80 patients for the *HDMX* transcript analysis and the patients consisted of 36 males and 44 females. The levels of *HDMX-S* and *HDMX-FL* were determined, as described in the materials and methods, in tumor samples that were taken before therapy. The levels of each transcript were determined and normalized to *GAPDH* expression levels. Sixteen tumors (20%) had no detectable *HDMX* transcript levels, 24 tumors (30%) had more *HDMX-FL* than *HDMX-S* transcripts, 24 tumors (30%) had equal amounts of *HDMX-S* and full-length transcripts, whereas 16 tumors (20%) had more *HDMX-S* than *HDMX-FL* transcripts. The p53 mutational status was successfully determined in 104 tumors of the 157 patients. Of the 104 tumor DNAs, 19 were found to have missense mutations in the p53 gene. Interestingly, similar to the observations made in the 3 cell panels, in the 46 tumors where both the levels of *HDMX-S* and *HDMX-FL* and mutational status were determined, we observed that the tumors with higher *HDMX-S* transcript levels than *HDMX-FL* were significantly enriched for p53 mutations ($P = 0.0337$, Fisher exact test, one-sided, Fig. 6A). The p53 mutation status alone could not effectively serve as a prognostic factor. Patients that had retained wild-type p53 in their sarcomas had longer survival

times than those with mutant p53, although the difference was not significant ($P = 0.469$, log-rank test, Fig. 6B; Supplementary Fig. S3A). However, the patients whose tumors had more *HDMX-S* than *HDMX-FL* transcripts had significantly shorter overall survival than those with equal or lower *HDMX-S* transcript levels ($P = 0.024$ log-rank test, Fig. 6C; Supplementary Fig. S3B and S3C) with a 5.746-fold higher risk of tumor-related death ($P = 0.01$, Fig. 6D).

Discussion

In this study, we began with the aim of further exploring the importance of the p53 pathway during the progression of osteosarcoma, through the analysis of the *HDMX-S/HDMX-FL* ratio and its association with HDMX protein levels in 22 osteosarcoma cell lines, as well as cancer progression and survival in 51 patients with osteosarcoma. Previously, we and others had reported increased mRNA expression of *HDMX-S* in various cancers (17, 22, 23). Interestingly, many tumors that showed increased *HDMX-S* mRNA levels had less *HDMX* full-length RNA and protein (22, 23) and correlated with later tumor stage and poorer survival. For example, we showed that even in cells expressing predominantly *HDMX-S* mRNA, only full-length HDMX protein could be detected (Fig. 4A and ref. 25). We propose that the HDMX-S protein is very unstable or inefficiently translated and, therefore, is unlikely to play an important, dominant role in cell proliferation. Here, we further showed that as the *HDMX-S/HDMX-FL* ratio increased, HDMX full-length protein decreased in the 22 osteosarcoma cell lines and the 37 breast cancer cell lines studied (Figs. 1, 2, and 4). For example, the osteosarcoma cell lines with the highest *HDMX-S/HDMX-FL* ratio expressed up to 9.5-fold less HDMX full-length protein.

In this study, we went on to explore the potential association of the *HDMX-S/HDMX-FL* ratio with osteosarcoma progression, as we and others had previously shown (17). Here, we studied 51 patients with high-grade osteosarcoma and, strikingly, found that high *HDMX-S/HDMX-FL* ratios correlated with faster metastatic progression (Fig. 4). Specifically, over 2 years, 62% of those with the highest *HDMX-S/HDMX-FL* ratios had presented with a metastasis, compared with only 8% of those with the lowest ratios. Interestingly, a subset of the cell lines used in this study had been previously analyzed for *in vivo* growth characteristics, including the capacity to metastasize (40). One of the tested cell lines was found to produce metastases in mice, HOS-143B, whereas the parental HOS cell line did not. Intriguingly, and in line with our observations in the patient cohort, we found a dramatically increased *HDMX-S/HDMX-FL* ratio and significantly decreased HDMX protein levels in HOS-143B cells compared with HOS cells (Fig. 1B and C).

Our observations in an osteosarcoma cell line panel and patient cohort suggest that the *HDMX-S/HDMX-FL* ratio positively correlates with less HDMX protein expression, as proposed earlier (25), and faster metastatic progression, as well as a trend to worse overall survival. In this study, we proposed that a reason why a cancer cell would not retain the oncogenic activity of HDMX is because it has already inhibited p53 signaling by mutations of other key regulatory genes in the pathway and, therefore, the cell is no longer under selective




Figure 6. High *HDMX-S/HDMX-FL* ratios but not p53 gene mutation associate with worse clinical outcome of patients with STS. A, column graph depicting the percentage of tumors with missense p53 mutations for tumors with either low ($n = 18$) or higher ($n = 28$) *HDMX-S/HDMX-FL* ratios. Tumors with higher ratios contain a greater percentage of p53 mutations. B, a Kaplan–Meier plot that displays overall survival for patients whose tumors contained either wild-type or mutant p53 ($n = 104$). The P value depicted on the plot is derived from a log-rank test. C, a Kaplan–Meier plot that displays the overall survival for those patients whose tumors contained high, intermediate, or low *HDMX-S/HDMX-FL* ratios ($n = 64$). The first P value is derived from a log-rank test comparing the patients with higher, equal, and lower ratios. The second P value is derived from a log-rank test comparing the patients with higher ratios to those with low ratios, as depicted by the asterisk. D, predicted survival curves for patients with different *HDMX-S/HDMX-FL* ratios ($n = 64$) derived from a Cox multivariate regression analysis that was adjusted to the known independent prognostic factors of STS that included tumor stage, resection type, tumor location, and tumor type. The P value depicted on the plot is derived through the comparison of the patients with higher ratios to those with low ratios, as is depicted by the asterisk.

pressure to sustain higher levels of HDMX. Furthermore, cells with deficient p53 activity could be under positive selection pressure to reduce HDMX levels as suggested by 2 recent studies, which report that full-length MDMX functions as a tumor suppressor in cells with deficient p53 function (41, 42). Indeed, our observations made in 3 cell panels, comprising a total of 115 different cell lines, lend support to this model. We observed that the cancer lines with higher *HDMX-S/HDMX-FL* ratios had significantly higher frequencies of 2 common p53 pathway mutations, namely p53 gene mutation and HDM2 overexpression (Table 1, Fig. 5). An interesting prediction of this model would be that the *HDMX-S/HDMX-FL* ratio could potentially serve as a more effective prognostic biomarker than p53 gene mutation, because alterations of other key p53 pathway genes (like HDM2 overexpression) that result in p53 pathway attenuation could be captured simultaneously. In this report,

we have presented observations that support this in a cohort of patients with STS, where *HDMX-S/HDMX-FL* ratios and p53 mutation status could be determined. We observed that the *HDMX-S/HDMX-FL* ratio was indeed a strikingly better prognostic indicator than p53 mutation. While these observations remain to be replicated in other patient cohorts and cancers, they indicate that the *HDMX-S/HDMX-FL* ratio could serve as an effective biomarker for p53 attenuation in cancer cells that could be used in a further personalization of therapeutic interventions in sarcomas as well as potentially other cancers.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Authors' Contributions

Conception and design: K. Lenos, A.M. Grawenda, G.L. Bond, A.G. Jochemsen
Development of methodology: A.M. Grawenda, G.L. Bond

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): K. Lenos, K. Lodder, M.L. Kuijjer, L.F. Grochola, F. Bartel, P.C.W. Hogendoorn, P. Wuerl

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): K. Lenos, A.M. Grawenda, K. Lodder, M.L. Kuijjer, E. Repapi, L.F. Grochola, F. Bartel, P.C.W. Hogendoorn, H. Taubert, G.L. Bond, A.G. Jochemsen

Writing, review, and/or revision of the manuscript: K. Lenos, A.M. Grawenda, M.L. Kuijjer, L.F. Grochola, F. Bartel, P.C.W. Hogendoorn, P. Wuerl, H. Taubert, G.L. Bond, A.G. Jochemsen

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): K. Lodder, A.F.A.S. Teunisse, P.C.W. Hogendoorn, P. Wuerl, H. Taubert

Study supervision: G.L. Bond, A.G. Jochemsen

Providing patient samples: A.-M. Cleton-Jansen

Acknowledgments

The authors thank Dr. Karoly Szuhai and Danielle de Jong for the use of previously unpublished osteosarcoma cell lines, Dr. Lam for the protein data of

the breast cancer cell lines, Drs. Konstantin Agelopoulos and Massimo Serra for providing the clinical samples from, respectively, the Westfälische Wilhelmsuniversität Münster and the Istituto Ortopedici Rizzoli, Bologna.

Grant Support

This work was supported by grants from the Dutch Cancer Society (UL-2006-3595 and 2008-4060), the Ludwig Institute for Cancer Research, the Development Fund-Oxford Cancer Research Centre-University of Oxford, the Deutsche Krebshilfe (grant 108424), the Wilhelm-Roux-Programm of the University of Halle-Wittenberg, and the Fritz-Thyssen-Stiftung (Az 10.09.2.117).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received January 27, 2012; revised May 18, 2012; accepted June 9, 2012; published OnlineFirst June 14, 2012.

References

- Raymond AK, Ayala AG, Knuutila S. Conventional osteosarcoma. In: Fletcher CDM, Unni KK, Mertens F, editors. World Health Organization classification of tumours pathology and genetics of tumours of soft tissue and bone. Lyon, France: IARC Press; 2002. p. 264-70.
- Lewis IJ, Nooij MA, Whelan J, Sydes MR, Grimer R, Hogendoorn PC, et al. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. *J Natl Cancer Inst* 2007;99:112-28.
- Buddingh EP, Anninga JK, Versteegh MI, Taminiau AH, Egeler RM, van Rijswijk CS, et al. Prognostic factors in pulmonary metastasized high-grade osteosarcoma. *Pediatr Blood Cancer* 2010;54:216-21.
- Gelderblom H, Jinks RC, Sydes M, Bramwell VH, van GM, Grimer RJ, et al. Survival after recurrent osteosarcoma: data from 3 European Osteosarcoma Intergroup (EOI) randomized controlled trials. *Eur J Cancer* 2011;47:895-902.
- Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. *Science* 1991;253:49-53.
- Hainaut P, Hollstein M. p53 and human cancer: the first ten thousand mutations. *Adv Cancer Res* 2000;77:81-137.
- Goh AM, Coffill CR, Lane DP. The role of mutant p53 in human cancer. *J Pathol* 2011;223:116-26.
- Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. *Nature* 2000;408:307-10.
- Yokoyama R, Schneider-Stock R, Radig K, Wex T, Roessner A. Clinicopathologic implications of MDM2, p53 and K-ras gene alterations in osteosarcomas: MDM2 amplification and p53 mutations found in progressive tumors. *Pathol Res Pract* 1998;194:615-21.
- Park HR, Jung WW, Bertoni F, Bacchini P, Park JH, Kim YW, et al. Molecular analysis of p53, MDM2 and H-ras genes in low-grade central osteosarcoma. *Pathol Res Pract* 2004;200:439-45.
- Wunder JS, Gokgoz N, Parkes R, Bull SB, Eskandarian S, Davis AM, et al. TP53 mutations and outcome in osteosarcoma: a prospective, multicenter study. *J Clin Oncol* 2005;23:1483-90.
- Kawai H, Wiederschain D, Yuan ZM. Critical contribution of the MDM2 acidic domain to p53 ubiquitination. *Mol Cell Biol* 2003;23:4939-47.
- Meulmeester E, Frenk R, Stad R, de GP, Marine JC, Vousden KH, et al. Critical role for a central part of Mdm2 in the ubiquitylation of p53. *Mol Cell Biol* 2003;23:4929-38.
- Ito M, Barys L, O'Reilly T, Young S, Gorbacheva B, Monahan J, et al. Comprehensive mapping of p53 pathway alterations reveals an apparent role for both SNP309 and MDM2 amplification in sarcomagenesis. *Clin Cancer Res* 2011;17:416-26.
- Shvarts A, Steegenga WT, Riteco N, van LT, Dekker P, Bazuine M, et al. MDMX: a novel p53-binding protein with some functional properties of MDM2. *EMBO J* 1996;15:5349-57.
- Marine JC, Jochemsen AG. Mdmx as an essential regulator of p53 activity. *Biochem Biophys Res Commun* 2005;331:750-60.
- Riemenschneider MJ, Knobbe CB, Reifenberger G. Refined mapping of 1q32 amplicons in malignant gliomas confirms MDM4 as the main amplification target. *Int J Cancer* 2003;104:752-7.
- Danovi D, Meulmeester E, Pasini D, Migliorini D, Capra M, Frenk R, et al. Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity. *Mol Cell Biol* 2004;24:5835-43.
- Ramos YF, Stad R, Attema J, Peltenburg LT, van der Eb AJ, Jochemsen AG. Aberrant expression of HDMX proteins in tumor cells correlates with wild-type p53. *Cancer Res* 2001;61:1839-42.
- Laurie NA, Donovan SL, Shih CS, Zhang J, Mills N, Fuller C, et al. Inactivation of the p53 pathway in retinoblastoma. *Nature* 2006;444:61-6.
- Pishas KI, Al-Ejeh F, Zinonos I, Kumar R, Evdokiou A, Brown MP, et al. Nutlin-3a is a potential therapeutic for ewing sarcoma. *Clin Cancer Res* 2011;17:494-504.
- Bartel F, Schulz J, Bohnke A, Blumke K, Kappler M, Bache M, et al. Significance of HDMX-S (or MDM4) mRNA splice variant overexpression and HDMX gene amplification on primary soft tissue sarcoma prognosis. *Int J Cancer* 2005;117:469-75.
- Prodosmo A, Giglio S, Moretti S, Mancini F, Barbi F, Avenia N, et al. Analysis of human MDM4 variants in papillary thyroid carcinomas reveals new potential markers of cancer properties. *J Mol Med (Berl)* 2008;86:585-96.
- Rallapalli R, Strachan G, Tuan RS, Hall DJ. Identification of a domain within MDMX-S that is responsible for its high affinity interaction with p53 and high-level expression in mammalian cells. *J Cell Biochem* 2003;89:563-75.
- Lenos K, Jochemsen AG. Functions of MDMX in the modulation of the p53-response. *J Biomed Biotechnol* 2011;2011:876173.
- Buddingh EP, Kuijjer ML, Duim RA, Burger H, Agelopoulos K, Myklebost O, et al. Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: a rationale for treatment with macrophage activating agents. *Clin Cancer Res* 2011;17:2110-9.
- Huvos AG. Bone tumors: diagnosis, treatment, and prognosis. Philadelphia, PA: W.B. Saunders company; 1991.
- Ottaviano L, Schaefer KL, Gajewski M, Huckenbeck W, Baldus S, Rogel U, et al. Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort. *Genes Chromosomes Cancer* 2010;49:40-51.
- da Costa CE, Szuhai K, van Eijk R, Hoogboom M, Sciort R, Mertens F, et al. No genomic aberrations in Langerhans cell histiocytosis as assessed by diverse molecular technologies. *Genes Chromosomes Cancer* 2009;48:239-49.
- Cleton-Jansen AM, Anninga JK, Braire-de BI, Romeo S, Oosting J, Egeler RM, et al. Profiling of high-grade central osteosarcoma and its putative progenitor cells identifies tumorigenic pathways. *Br J Cancer* 2009;101:1909-18.

31. Elstrodt F, Hollestelle A, Nagel JH, Gorin M, Wasielewski M, van den Ouweland A, et al. BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants. *Cancer Res* 2006;66:41–5.
32. Wasielewski M, Elstrodt F, Klijn JG, Berns EM, Schutte M. Thirteen new p53 gene mutants identified among 41 human breast cancer cell lines. *Breast Cancer Res Treat* 2006;99:97–101.
33. Lam S, Lodder K, Teunisse AF, Rabelink MJ, Schutte M, Jochemsen AG. Role of Mdm4 in drug sensitivity of breast cancer cells. *Oncogene* 2010;29:2415–26.
34. Chen J, Marechal V, Levine AJ. Mapping of the p53 and mdm-2 interaction domains. *Mol Cell Biol* 1993;13:4107–14.
35. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, et al. *In vivo* activation of the p53 pathway by small-molecule antagonists of MDM2. *Science* 2004;303:844–8.
36. Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P, Olivier M. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. *Oncogene* 2007;26:2157–65.
37. Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. *Nat Rev Cancer* 2006;6:813–23.
38. Caron de Fromental C, Soussi T. TP53 tumor suppressor gene: a model for investigating human mutagenesis. *Genes Chromosomes Cancer* 1992;4:1–15.
39. The TP53 Web Site [cited 2012 Mar 1]. Available from: <http://p53.free.fr>.
40. Mohseny AB, Machado I, Cai Y, Schaefer KL, Serra M, Hogendoorn PC, et al. Functional characterization of osteosarcoma cell lines provides representative models to study the human disease. *Lab Invest* 2011;91:1195–205.
41. Matijasevic Z, Steinman HA, Hoover K, Jones SN. MdmX promotes bipolar mitosis to suppress transformation and tumorigenesis in p53-deficient cells and mice. *Mol Cell Biol* 2008;28:1265–73.
42. Matijasevic Z, Krzywicka-Racka A, Sluder G, Jones SN. MdmX regulates transformation and chromosomal stability in p53-deficient cells. *Cell Cycle* 2008;7:2967–73.

Cancer Research

The Journal of Cancer Research (1916–1930) | The American Journal of Cancer (1931–1940)

Alternate Splicing of the p53 Inhibitor HDMX Offers a Superior Prognostic Biomarker than p53 Mutation in Human Cancer

Kristiaan Lenos, Anna M. Grawenda, Kirsten Lodder, et al.

Cancer Res 2012;72:4074-4084. Published OnlineFirst June 14, 2012.

Updated version Access the most recent version of this article at:
doi:[10.1158/0008-5472.CAN-12-0215](https://doi.org/10.1158/0008-5472.CAN-12-0215)

Supplementary Material Access the most recent supplemental material at:
<http://cancerres.aacrjournals.org/content/suppl/2012/06/14/0008-5472.CAN-12-0215.DC1>

Cited articles This article cites 39 articles, 13 of which you can access for free at:
<http://cancerres.aacrjournals.org/content/72/16/4074.full#ref-list-1>

Citing articles This article has been cited by 7 HighWire-hosted articles. Access the articles at:
<http://cancerres.aacrjournals.org/content/72/16/4074.full#related-urls>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://cancerres.aacrjournals.org/content/72/16/4074>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.